Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
122.72
+17.78 (16.94%)
At close: Aug 25, 2026, 4:00 PM EDT
122.72
0.00 (0.00%)
After-hours: Aug 25, 2026, 4:10 PM EDT

Inhibrx Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-1.30.21.81.327.23
Revenue Growth
-550.00%-88.89%36.88%-81.81%-43.89%
Cost of Revenue
103113.03177.84191.64101.671.44
Gross Profit
-103-111.73-177.64-189.84-100.29-64.21
Selling, General & Admin
24.8123.344.6429.3515.0412.36
Operating Expenses
24.8123.344.6429.3515.0412.36
Operating Income
-127.81-135.03-222.29-219.19-115.32-76.56
Interest Expense
-15.57-12.2-13.49-31.84--
Interest & Investment Income
5.377.5510.9411.92--
Earnings From Equity Investments
----1.63--
Other Non Operating Income (Expenses)
-0.17-0.380.08-0.580-5.2
EBT Excluding Unusual Items
-138.18-140.05-224.76-241.32-115.32-81.77
Merger & Restructuring Charges
---109.16-0.04--
Other Unusual Items
--2,021---
Pretax Income
-138.18-140.051,688-241.36-115.32-81.77
Income Tax Expense
000000
Net Income
-138.18-140.061,688-241.36-115.33-81.77
Net Income to Common
-138.18-140.061,688-241.36-115.33-81.77
Net Income Growth
------
Shares Outstanding (Basic)
161515124038
Shares Outstanding (Diluted)
161515124038
Shares Change
0.61%3.36%27.17%-70.62%5.52%50.47%
EPS (Basic)
-8.88-9.04114.01-20.48-2.88-2.15
EPS (Diluted)
-8.88-9.04112.62-20.48-2.88-2.15
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-131.9-129.83-197.01-197.9-91.5-
Free Cash Flow Per Share
-8.47-8.38-13.15-16.80-2.28-
Operating Margin
--10386.54%-111143.50%-12176.94%-8769.81%-1058.83%
Profit Margin
--10773.46%843786.00%-13408.94%-8769.96%-1130.80%
Free Cash Flow Margin
--9986.54%-98503.00%-10994.56%-6957.95%-
EBITDA
-125.6-132.54-220-217.99-114.1-
D&A For EBITDA
2.212.482.291.191.23-
EBIT
-127.81-135.03-222.29-219.19-115.32-76.56
Revenue as Reported
-1.30.21.81.327.23
SEC Filings: 10-K · 10-Q